FR22C1045I1 - Conjugués protéine-polymère - Google Patents

Conjugués protéine-polymère

Info

Publication number
FR22C1045I1
FR22C1045I1 FR22C1045C FR22C1045C FR22C1045I1 FR 22C1045 I1 FR22C1045 I1 FR 22C1045I1 FR 22C1045 C FR22C1045 C FR 22C1045C FR 22C1045 C FR22C1045 C FR 22C1045C FR 22C1045 I1 FR22C1045 I1 FR 22C1045I1
Authority
FR
France
Prior art keywords
protein
polymer conjugates
conjugates
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1045C
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1045(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR22C1045I1 publication Critical patent/FR22C1045I1/fr
Application granted granted Critical
Publication of FR22C1045I2 publication Critical patent/FR22C1045I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR22C1045C 2007-08-16 2022-08-26 Conjugués protéine-polymère Active FR22C1045I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16
PCT/US2008/073290 WO2009023826A1 (fr) 2007-08-16 2008-08-15 Conjugués protéine-polymère

Publications (2)

Publication Number Publication Date
FR22C1045I1 true FR22C1045I1 (fr) 2022-10-14
FR22C1045I2 FR22C1045I2 (fr) 2023-12-29

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1045C Active FR22C1045I2 (fr) 2007-08-16 2022-08-26 Conjugués protéine-polymère

Country Status (30)

Country Link
US (1) US8143214B2 (fr)
EP (2) EP4129343A1 (fr)
JP (1) JP5613050B2 (fr)
KR (1) KR101588465B1 (fr)
CN (1) CN101367872B (fr)
AR (1) AR067964A1 (fr)
AU (1) AU2008286742B2 (fr)
BR (1) BRPI0814482B8 (fr)
CA (1) CA2696478C (fr)
CL (1) CL2008002399A1 (fr)
CY (1) CY1125751T1 (fr)
DK (1) DK2205281T3 (fr)
EA (1) EA018111B1 (fr)
ES (1) ES2924727T3 (fr)
FR (1) FR22C1045I2 (fr)
HR (1) HRP20220937T3 (fr)
HU (2) HUE059551T2 (fr)
LT (1) LT2205281T (fr)
MX (1) MX2010001750A (fr)
MY (1) MY149148A (fr)
NL (1) NL301195I2 (fr)
NO (1) NO2022038I1 (fr)
NZ (1) NZ583831A (fr)
PL (1) PL2205281T3 (fr)
PT (1) PT2205281T (fr)
SI (1) SI2205281T1 (fr)
TW (1) TWI381851B (fr)
UA (1) UA103158C2 (fr)
WO (1) WO2009023826A1 (fr)
ZA (1) ZA201001777B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072850A1 (es) * 2008-07-31 2010-09-22 Pharmaessentia Corp Conjugados peptido-polimero
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
MX2017005244A (es) 2014-11-06 2017-08-18 Pharmaessentia Corp Regimen de dosificacion para interferon pegilado.
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
MXPA02001969A (es) * 1999-08-27 2003-07-21 Maxygen Aps Nuevas moleculas similares a interferon beta.
CA2390292A1 (fr) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Conjugues d'interferon gamma
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
KR20070072924A (ko) * 2001-11-20 2007-07-06 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
CA2510040C (fr) * 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Reactifs polymeriques et conjugues polymeres-biomolecules comportant des liens carbamate
US7405198B2 (en) * 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
AP2007003919A0 (en) 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (fr) * 2005-03-11 2006-09-14 Siegfried Ltd. Conjugues de proteines et de dipolymeres et leurs procedes de preparation
EP1869079A2 (fr) * 2005-03-11 2007-12-26 Siegfried Ltd. Conjugues di-polymere-proteine et procedes de preparation de ceux-ci
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CN101636414B (zh) 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
DK2205281T3 (da) 2022-08-15
FR22C1045I2 (fr) 2023-12-29
AU2008286742A1 (en) 2009-02-19
CY1125751T1 (el) 2023-06-09
NL301195I1 (fr) 2022-08-31
HUE059551T2 (hu) 2022-11-28
WO2009023826A1 (fr) 2009-02-19
NZ583831A (en) 2012-06-29
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
EP2205281B1 (fr) 2022-06-29
CN101367872A (zh) 2009-02-18
EA018111B1 (ru) 2013-05-30
AR067964A1 (es) 2009-10-28
US20090053177A1 (en) 2009-02-26
LT2205281T (lt) 2022-09-26
MX2010001750A (es) 2010-06-01
NL301195I2 (nl) 2023-03-02
EA201070282A1 (ru) 2010-08-30
SI2205281T1 (sl) 2022-11-30
US8143214B2 (en) 2012-03-27
NO2022038I1 (no) 2022-09-02
ES2924727T3 (es) 2022-10-10
HRP20220937T3 (hr) 2022-09-30
TW200916116A (en) 2009-04-16
KR20100076945A (ko) 2010-07-06
EP2205281A1 (fr) 2010-07-14
BRPI0814482B8 (pt) 2021-11-23
CN101367872B (zh) 2013-11-20
ZA201001777B (en) 2010-12-29
HUS2200039I1 (hu) 2022-09-28
EP4129343A1 (fr) 2023-02-08
JP2010536788A (ja) 2010-12-02
AU2008286742B2 (en) 2014-05-29
CA2696478A1 (fr) 2009-02-19
CA2696478C (fr) 2018-10-09
JP5613050B2 (ja) 2014-10-22
CL2008002399A1 (es) 2009-01-02
EP2205281A4 (fr) 2014-10-08
BRPI0814482B1 (pt) 2021-02-02
PL2205281T3 (pl) 2022-12-12
UA103158C2 (ru) 2013-09-25
KR101588465B1 (ko) 2016-01-25
PT2205281T (pt) 2022-08-02
BRPI0814482A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
DE502007001207D1 (de) Elektrosaugkopf
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0811451A2 (pt) Exopolissacarídeo
DK2125048T3 (da) Præparat
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812994A2 (pt) Microbiocidas
FR22C1045I2 (fr) Conjugués protéine-polymère
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003196A5 (de) Handpipettiergerät
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
CU20090155A7 (es) Macrolidos
DE102007038931A8 (de) Fadenlagennähwirkstoffe
DE502008000815D1 (de) Kraftfahrzeugsitzverstellantrieb
DE112008001534A5 (de) Anreihgussform
DE502007005002D1 (de) Durchlaufsägevorrichtung
DE112008003669A5 (de) Abkühlanordnung
DE502008002186D1 (de) Ringextruder
AT9563U3 (de) Wirbelsäulenzuggurtung